April 15 (Reuters) - Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease helped significantly reduce liver fat in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | +5.49% | +3.10% | -13.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.51% | 10.94M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo's fatty liver disease drug meets main goal in mid-stage study